iBio Receives Patent Allowances for Pandemic Influenza Therapeutics

March 27, 2014 iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza. “The antibodies covered by these patents are designed to block critical functions of the influenza virus necessary for infection or replication,” said Wayne P. Fitzmaurice, Ph.D., iBio’s vice president of intellectual property. …